SD221012-003 page 1 of 1

PharmLabs San Diego Certificate of Analysis

3421 Hancock St, Second Floor, San Diego, CA 92110 | License: C8-0000098-LIC ISO/IEC 17025:2017 Certification L17-427-1 | Accreditation #85368

sample Zombi Extrax - Lemon Kush

|--|

Sample ID SD221012-003 (53472)	Matrix Concentrate (Inhalable Cannabis Good)			
Distributor License 604034860	Address 1 Vanderbil	bilt, Irvine CA, 92618 Name Savage Enterpri	ses	
Sampled -	Received Oct 11, 2022	Reported Oct 13, 2022		
Analyses executed CANX				

Laboratory note: The estimated concentration of the unknown peak in the sample is 6.23% | Currently PharmLabs laboratory can not confirm an unidentified peak in your chromatogram due to interference (only with highly concentrated D8 products) from which we believe to be either (+)d8-THC or d9-THC. At this time there are no reference standards available for (+)d8-THC. (+)d8-THC is a different compound from the main (-)d8-THC cannobinoid and, therefore, these two compounds may have different efficacies. Using the most advanced instruments and techniques available, the separation of (+)d8-THC is problematic for the scientific community as a whole. PharmLabs believes the unidentified peak to be a combination of (+)d8-THC with the majority, if not all, of the concentration being (+)d8-THC. Total (+/-) D8 Concentration is estimated to be ±44.4%

CANX - Cannabinoids Analysis

Analyzed Oct 13, 2022 | Instrument HLPC Measurement Uncertainty at 95% confidence7.806%

Analyte	LOD mg/g	LOQ mg/g	Result %	Result mg/g
11-Hydroxy-∆8-Tetrahydrocannabivarin (11-Hyd-∆8-THCV)	0.013	0.041	ND	ND
Cannabidiorcin (CBDO)	0.002	0.007	ND	ND
Abnormal Cannabidiorcin (a-CBDO)	0.01	0.031	ND	ND
(+/-)-9B-hydroxy-Hexahydrocannibinol (9b-HHC)	0.012	0.036	ND	ND
11-Hydroxy-∆8-Tetrahydrocannabinol (11-Hyd-∆8-THCV)	0.007	0.021	ND	ND
Cannabidiolic Acid (CBDA)	0.001	0.16	ND	ND
Cannabigerol Acid (CBGA)	0.001	0.16	ND	ND
Cannabigerol (CBG)	0.001	0.16	0.27	2.73
Cannabidiol (CBD)	0.001	0.16	1.13	11.31
(S)-THD (s-THD)	0.013	0.041	2.59	25.88
(R)-THD (r-THD)	0.025	0.075	5.71	57.09
Tetrahydrocannabivarin (THCV)	0.001	0.16	ND	ND
Δ8-tetrahydrocannabivarin (Δ8-THCV)	0.021	0.064	ND	ND
Fetrahydrocannabutol (Δ9-THCB)	0.013	0.038	3.84	38.38
Cannabinol (CBN)	0.001	0.16	1.12	11.23
exo-THC (exo-THC)	0.016	0.8	ND	ND
Fetrahydrocannabinol (Δ9-THC)	0.003	0.16	UI	UI
Δ8-tetrahydrocannabinol (Δ8-THC)	0.004	0.16	44.48	444.80
6aR,9S)-Δ10-Tetrahydrocannabinol ((6aR,9S)-Δ10)	0.015	0.16	0.77	7.65
Hexahydrocannabinol (S Isomer) (9s-HHC)	0.017	0.16	ND	ND
6aR,9R)-Δ10-Tetrahydrocannabinol ((6aR,9R)-Δ10)	0.007	0.16	11.5 4	115.42
Hexahydrocannabinol (R Isomer) (9r-HHC)	0.016	0.16	ND	ND
Fetrahydrocannabinolic Acid (THCA)	0.001	0.16	ND	ND
Δ9-Tetrahydrocannabihexol (Δ9-THCH)	0.024	0.071	ND	ND
Cannabinol Acetate (CBNO)	0.014	0.043	ND	ND
Δ9-Tetrahydrocannabiphorol (Δ9-THCP)	0.017	0.16	0.64	6.44
Δ8-Tetrahydrocannabiphorol (Δ8-THCP)	0.041	0.16	0.17	1.66
Δ8-THC-O-acetate (Δ8-THCO)	0.076	0.16	ND	ND
9(S)-HHCP (s-HHCP)	0.031	0.094	ND	ND
Δ9-THC-O-acetate (Δ9-THCO)	0.066	0.16	ND	ND
9(R)-HHCP (r-HHCP)	0.026	0.079	ND	ND
3-octyl-Δ8-Tetrahydrocannabinol (Δ8-THC-C8)	0.067	0.204	1.96	19.58
Total THC (THCa * 0.877 + THC)			ND	ND
Total CBD (CBDa * 0.877 + CBD)			1.13	11.31
Total CBG (CBGa * 0.877 + CBG)			0.27	2.73
Total HHC (9r-HHC + 9s-HHC)			ND	ND
TOTAL CANNABINOIDS			74.22	742.20

UI Not Identified ND Not Detected NA Not Applicable NT Not Reported LOD Limit of Detection LOQ Limit of Quantification <LOQ Detected NUCU. Above upper limit of linearity >ULCU. Above upper limit of linearity CFU/Q colony forming Units per 1 gram TNTC Too Numerous to Count







Authorized Signature

Brandon Starr

Brandon Starr, Lab Manager Thu, 13 Oct 2022 15:59:39 -0700



PharmLabs San Diego | 3421 Hancock St, Second Floor, San Diego, CA 92110 | 619.356.0898 | ISO/IEC 17025:2017 Certification L17-427-1 "This report shall not be reproduced except in full, without the written approval of the lab. This report is for informational purposes only and should not be used to diagnose, treat or prevent any disease. Results are only for samples and batches indicated. Results are reported on an "as received" basis, unless indicated otherwise. When a Pass/Fall status is reported, that status is intended to be in accordance with federal, state and local lows which are required for the customer to be in compliance. The measurement of uncertainty is not included in the Pass/Fall evolution unless explicition unless explicition, state or local lows and has been reported on the retrificate of analysis. Ressurement of uncertainty is available upon request.

QA Testing